New hope for tough RA cases? phase 1 trial of CLN-978 begins

NCT ID NCT06994143

Recruiting now Disease control Sponsor: Cullinan Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 24, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug, CLN-978, in 37 adults with rheumatoid arthritis that hasn't responded to other treatments. The goal is to see if the drug is safe and can control the disease by lowering certain immune cells. Participants must have active arthritis and signs that B cells are involved in their condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fondazione Policlinico Universitario A Gemelli
RECRUITING

Rome, 00168, Italy

Contact Phone: •••-•••-••••
University Hospital Erlangen
RECRUITING

Erlangen, 91054, Germany

Contact Phone: •••-•••-••••
University Hospital Heidelberg
RECRUITING

Heidelberg, 69120, Germany

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RHEUMATOID ARTHRITIS (RA)